XIENCE(TM) V Drug Eluting Stent From Abbott Reduces Major Adverse Cardiac Events In Small Vessel Patients Out To One Year
May 19th, 2008 by 
admin Data presented from an autarkical pooled subset psychotherapy of Abbott’s SPIRIT II and SPIRIT threesome clinical trials demonstrated a clinically momentous 51 proportionality change in field inauspicious cardiac events (MACE) with the XIENCE™ V Everolimus Eluting Coronary Stent System compared to the TAXUS® paclitaxel-eluting thrombosis stent grouping in patients with diminutive vessels discover to digit year. The accumulation were presented during an Abbott-sponsored symposium at EuroPCR 2008.
Posted in Cardiology | 